Anakinra as a Treatment for Hydradenitis Suppurativa

Inclusion Criteria: 1\) Signed informed consent form with Confirmed diagnosis of hidradenitis suppurativa with moderate or severe disease activity Exclusion Criteria: 1. Use of the following therapies: * Etanercept in the 4 weeks prior to the baseline visit (Day 1) * Adalimumab in the 8 weeks prior to the baseline visit (Day 1) * Infliximab in the 12 weeks prior to the baseline visit (Day 1) * Any other investigational biologics in the 8 weeks prior to the baseline visit (Day 1) * Leflunomide in the 4 weeks prior to the baseline visit (Day 1) • Thalidomide in the 4 weeks prior to the baseline visit (Day 1) * Cyclosporine in the 4 weeks prior to the baseline visit (Day 1) * I.V. immunoglobulin (I.V. Ig) in the 8 weeks prior to the baseline visit (Day 1) * 6-Mercaptopurine, azathioprine, cyclophosphamide, or chlorambucil in the 12 weeks prior to the baseline visit (Day 1) * Colchicine, dapsone, mycophenolate mofetil \& systemic antibiotics in the 3 weeks prior to the baseline visit (Day 1) * Corticosteroids "20mg/day or \>0.4 mg/kg, whichever applies, in the 1 week prior to the baseline visit (Day 1) 2. history of immunocompromise including HIV infection 3. positive Hep B surface antigen -